Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 1000 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR Using Technology to Find Cancers Early and Exercise Improves Sexual Health... July 31, 2023 5 ways cancer can impact sexual wellbeing May 17, 2023 A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... October 31, 2024 Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... July 12, 2021 Load more HOT NEWS Healthy and Delicious Figs EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... An Oncology Hospital at Home Model of Acute Care Shows Promise
